By writer to news.google.com
BRISBANE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology firm centered on creating and commercializing transformative therapies for sufferers with severe immunological ailments, right this moment introduced that the Firm’s administration crew will current and take part in one-on-one conferences on the following investor conferences, as detailed beneath:
Piper Sandler 34th Annual Healthcare Convention
Format: Presentation
Date and Time: Tuesday, November 29, 2022, 9:50 – 10:10 AM ET
Webcast: https://event.webcasts.com
fifth Annual Evercore ISI HealthCONx Convention
Format: Fireplace Chat
Date and Time: Thursday, December 1, 2022, 12:10 – 12:30 PM ET
Webcast: https://wsw.com/webcast
A replay of the displays will likely be accessible for 90 days and may be accessed by visiting the “ Investor Calendar ” part of the Vera Therapeutics web site.
About Vera Therapeutics
Vera Therapeutics is a late-stage biotechnology firm centered on creating therapies for severe immunological ailments. Vera’s mission is to advance therapies that focus on the supply of immunologic ailments with a purpose to change the usual of look after sufferers. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection as soon as weekly that blocks each B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to provide autoantibodies contributing to sure autoimmune ailments, together with IgA nephropathy (IgAN), also referred to as Berger’s illness, and lupus nephritis. As well as, Vera is evaluating extra ailments the place the discount of autoantibodies by atacicept might show medically helpful. Vera can also be creating MAU868, a monoclonal antibody designed to neutralize an infection with BK Virus, a polyomavirus that may have devastating penalties in sure settings equivalent to kidney transplant. For extra info, please go to www.veratx.com.
For extra info, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
Media Contact:
Kathy Vincent
Greig Communications, Inc.
Copyright 2022 GlobeNewswire, Inc.
— to news.google.com
